Triple GIP/GLP-1/Glucagon Receptor Agonist4 mgInvestigational

4 mg Retatrutide Dosage Calculator

Calculate the exact units for your 4 mg retatrutide escalation dose at any available vial concentration.

Retatrutide is an investigational medication currently in clinical trials. It has not been approved by the FDA for any indication.

050100

How many units is 4 mg of Retatrutide at 2 mg/mL?

Draw

200units

2.00 mL on a U-100 insulin syringe

4 mg ÷ 2 mg/mL × 100 = 200 units

This dose exceeds 50 units (0.5 mL). Volumes greater than 0.5 mL may be uncomfortable for subcutaneous injection. Consult your provider about splitting the dose into two injections.

For educational purposes only. Always follow your provider's instructions.

Quick Reference Table

All dose × concentration combinations

Dose2 mg/mL5 mg/mL10 mg/mL
1 mg502010
2 mg100*4020
4 mg200*80*40
8 mg400*160*80*
12 mg600*240*120*

Values in U-100 insulin syringe units

* Exceeds 50 units (0.5 mL) — may require splitting into two injections

There's an easier way

Tired of calculating doses?

We handle everything — the prescription, the right dose, and shipping straight to your door. No math, no hassle.

Get Started

2-min quiz · Free consultation · No commitment

About the 4 mg Dose

The 4 mg dose is a mid-escalation step in the retatrutide clinical trial protocol, used during weeks 9 through 12. At this dose, the triple-receptor agonist mechanism is producing meaningful metabolic effects. Phase 2 trial data showed that even the 4 mg cohort achieved significant weight loss, though the higher 8 mg and 12 mg doses were more effective.

Frequently Asked Questions

In a 10 mg/mL vial, 4 mg retatrutide equals 40 units. The calculation is (4 / 10) x 100 = 40 units. In a 5 mg/mL vial, it would be 80 units, and in a 2 mg/mL vial, it would be 200 units.

The 4 mg dose is used during weeks 9 through 12, which is the third step in the escalation schedule. The full trial protocol was: 1 mg (weeks 1-4), 2 mg (weeks 5-8), 4 mg (weeks 9-12), 8 mg (weeks 13-16), and 12 mg (weeks 17 onward). The dose doubles at each step from 1 mg through 4 mg before transitioning to the higher therapeutic range.

The Phase 2 clinical trial showed meaningful weight loss at 4 mg retatrutide, though specific percentages for this dose tier were lower than the headline-grabbing 24.2% seen at 12 mg over 48 weeks. The 4 mg dose cohort still outperformed placebo significantly, demonstrating that even moderate doses of this triple-agonist produce clinically relevant results.

The doubling pattern from 1 mg to 2 mg to 4 mg follows a logarithmic escalation approach common in early clinical trials. This allows researchers to assess the dose-response relationship across a wide range. The larger jumps at lower doses are generally well-tolerated because the absolute milligram increase remains moderate.

Other Retatrutide Doses

1 mg Retatrutide2 mg Retatrutide8 mg Retatrutide12 mg Retatrutide

Related Pages

Retatrutide CalculatorRetatrutide Dosing

Ready to Get Started?

Take our 2-minute quiz to see if you qualify for GLP-1 treatment.

Start Quiz

Free consultation. No commitment.